Recludix Pharma’s REX-7117 Shows Promise in Preclinical Studies of Th17-mediated Skin Inflammation
Oral selective STAT3 inhibitors including REX-7117 showed efficacy and safety potential in preclinical models of Th17-mediated skin inflammation, according to data presented in an oral plenary session at the Society for Investigative Dermatology (SID) Annual Meeting in Dallas, TX. Data demonstrated that REX-7117 achieves deep, durable, and selective STAT3 inhibition and exhibits similar efficacy to […]